[ad_1]
The vaccine developed against the new coronavirus developed by the company AstraZeneca could be available for use at the end of December, announced the chief executive of the pharmaceutical manufacturer. The company is now awaiting approvals issued by regulatory authorities in the drug market, DPA reports, according to Agerpres.
“Regulators are constantly analyzing our data. If it’s quick when we’re ready, we can start vaccinating people in January, possibly even late December,” said Pascal Soriot, CEO. AstraZeneca, quoted in Saturday’s edition of the Swedish daily Dagens Nyheter.
AstraZeneca, a British-Swedish company, is collaborating with the University of Oxford in the United Kingdom to manufacture a possible vaccine against the new coronavirus, considered one of the most promising candidates in the world in the race to find an effective treatment to end the pandemic. COVID-19.
“We may never get any money from him (from the AstraZeneca vaccine, no). No one knows how often people will have to get vaccinated. If our vaccine is effective and protects people for many years, and the disease goes away.” Then no there will be a market, “said Pascal Soriot.
Uncertain profit
He also mentioned that many experts still believe that people will have to get vaccinated again after a while. “If this has to be done annually, then we will be able to get money from it (the vaccine, no) starting in 2022,” added the AstraZeneca CEO.
“But we have to make sure that our vaccine really works,” he said.
The vaccine developed by AstraZeneca entered Phase 3 of its clinical trials in September. Those studies were temporarily halted due to concerns about the health of a UK volunteer, but were later resumed.
The European Union, the United States, the United Kingdom, Japan and Brazil have signed initial contracts with AstraZeneca to purchase large quantities of the vaccine if it is approved by regulatory authorities in the drug market.
